UpStream Bio Inc. Stock Price, News & Analysis

Upstream Bio (Nasdaq: UPB) said CEO Rand Sutherland, MD will participate in three investor events in November 2025: Truist Securities BioPharma Symposium in New York on Nov 6, 2025 at 8:10 a.m. ET (panel); Stifel 2025 Healthcare Conference in New York on Nov 11, 2025 at 9:20 a.m. ET (presentation); and TD Cowen Immunology and Inflammation Summit (virtual) on Nov 12, 2025 at 10:30 a.m. ET (fireside chat).

Live webcasts of the Stifel and Cowen presentations will be available under the Events tab in the Investors section of Upstream Bio’s website on the day of each event, and replays will be posted after the presentations.

Upstream Bio (Nasdaq: UPB) presented structural and mechanistic data for verekitug, their TSLP receptor-targeting treatment for inflammatory diseases, at the European Respiratory Society Congress. The data revealed verekitug's unique mechanism of action, showing high-affinity binding to the TSLP receptor and ability to outcompete TSLP binding even with preformed heterodimeric receptor complexes.

The company recently reported successful Phase 2 results in chronic rhinosinusitis with nasal polyps, demonstrating significant effects with 12-week dosing intervals. Additional Phase 2 data for severe asthma is expected in Q1 2026. The preclinical findings suggest verekitug's receptor-targeting approach may offer advantages over current TSLP ligand-targeting therapies, potentially enabling less frequent dosing compared to existing biologics.

Upstream Bio (Nasdaq: UPB), a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in an upcoming investor event. CEO Rand Sutherland, MD will engage in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.

The presentation will be accessible via live webcast in the Events section of the company's investor relations website, with a replay available after the event.

Upstream Bio (NASDAQ:UPB) announced positive top-line results from its Phase 2 VIBRANT trial evaluating verekitug for treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met its primary endpoint with verekitug, dosed every 12 weeks, achieving a significant placebo-adjusted reduction in nasal polyp score of -1.8 (p<0.0001).

The study demonstrated significant improvements in key secondary endpoints, including a -0.8 reduction in nasal congestion score (p=0.0003) and 76% reduction (p=0.03) in need for surgery or systemic corticosteroids. The drug showed a favorable safety profile with no serious adverse events reported. Notably, verekitug's clinical effect appears to meet or exceed that of other biologics in CRSwNP at 24 weeks.

Upstream Bio (NASDAQ:UPB) has scheduled a conference call and webcast for September 2, 2025, at 8:00 a.m. ET to present top-line data from its Phase 2 VIBRANT trial. The study evaluates verekitug, a unique monoclonal antibody targeting TSLP receptor, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

The VIBRANT trial (NCT06164704) is a global, randomized, placebo-controlled study where participants received either 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The trial's primary endpoint focuses on measuring changes in endoscopic nasal polyp score at Week 24.

Upstream Bio (NASDAQ:UPB) reported Q2 2025 financial results and clinical progress for its lead drug verekitug, the only monoclonal antibody targeting TSLP receptor in development. The company highlighted three key clinical trials: VIBRANT (CRSwNP) with top-line data expected in Q3 2025, VALIANT (severe asthma) with results in Q1 2026, and VENTURE (COPD) which dosed its first patient in July 2025.

Financially, Upstream reported cash position of $393.6 million, expected to fund operations through 2027. Q2 2025 showed a net loss of $40.0 million, up from $14.7 million in Q2 2024, primarily due to increased R&D expenses of $37.9 million and G&A expenses of $7.4 million.

[ "Strong cash position of $393.6 million, funding operations through 2027", "Completed enrollment in Phase 2 severe asthma trial ahead of Q1 2026 data readout", "On track for CRSwNP Phase 2 trial results in Q3 2025", "Expanded clinical program with first COPD patient dosed in July 2025" ]

Upstream Bio (NASDAQ:UPB) has initiated dosing in its Phase 2 clinical trial, VENTURE, evaluating verekitug for Chronic Obstructive Pulmonary Disease (COPD). The trial will assess approximately 670 adults with moderate-to-severe COPD, testing doses of 100 mg every 12 weeks or 400 mg every 24 weeks versus placebo.

This expansion marks verekitug's third indication in development, alongside ongoing Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma. The company has completed enrollment for both existing trials, with data expected in Q3 2025 for CRSwNP and Q1 2026 for severe asthma.

Verekitug, as the only known biologic targeting the TSLP receptor, aims to improve COPD treatment through less frequent dosing and potentially differentiated efficacy compared to existing biologics.

Upstream Bio (UPB) presented translational pharmacology modeling data for verekitug, their novel antibody antagonist targeting the TSLP receptor, at the EAACI Congress. The data demonstrates verekitug's greater potency compared to tezepelumab in treating inflammatory diseases. The modeling shows complete and sustained inhibition of the TSLP/TSLPR complex and predicts greater reduction in FeNO, a lung inflammation biomarker. This superior efficacy is attributed to lower TSLP receptor expression levels and slower protein turnover compared to the ligand. Verekitug is currently in Phase 2 trials for severe asthma, COPD, and CRSwNP, with topline data expected in Q3 2025 for CRSwNP and H1 2026 for severe asthma.

Upstream Bio (Nasdaq: UPB) announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK. The presentation will showcase translational pharmacology modeling data for their drug verekitug, which targets the TSLP receptor for inflammatory diseases, particularly severe respiratory disorders. The data demonstrates verekitug's enhanced potency compared to treatments targeting the TSLP ligand, such as tezepelumab. Dr. Ashish Kalra, VP of Translational Research, will present these findings on June 15, 2025, focusing on the in silico system pharmacology modeling insights that explain the drug's superior potency mechanism.